Prostacyclin Analogs: Antiaggregatory Potency and Enhancement of cAMP Levels in Human Platelet Rich Plasma

Please copy the URL and add it into your RSS Feed Reader.

Thromb Haemost 1979; 42(04): 1340-1343
DOI: 10.1055/s-0038-1657030

Letter to the Editor

Schattauer GmbH Stuttgart

Authors

A Dembinska-Kiec

Zentrum für Pharmakologie u. Toxikologie, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany
W Rücker

Zentrum für Pharmakologie u. Toxikologie, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany
P S Schönhöfer

Zentrum für Pharmakologie u. Toxikologie, Medizinische Hochschule Hannover, D-3000 Hannover 61, Fed. Rep. Germany
C Gandolfi

Farmitalia Carlo Erba, Via Carlo Imbonati 24, 1-20159 Milan/Italy

Publication Date:
23 August 2018 (online)

References
1 Gilman AG. 1970; A protein binding assay for adenosine-3’, 5’-cyclic monophosphate. Proc. Nat. Acad. Sci. USA 67: 305

Reference Link Ris
Crossref PubMed Search in Google Scholar
2 Gorman RR, Bunting S, Miller OV. 1977; Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377

Reference Link Ris
Crossref PubMed Search in Google Scholar
3 Moncada S, Gryglewski RJ, Bunting S, Vane JR. 1976; An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (London) 263: 663

Reference Link Ris
Crossref PubMed Search in Google Scholar
4 Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane RJ. 1976; Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12: 685

Reference Link Ris
Crossref PubMed Search in Google Scholar